May 10, 2022 -- The cell therapy industry is facing a significant but addressable challenge when it comes to scaling up manufacturing, according to Bob Newman, PhD, chief scientific officer at FujiFilm Irvine Scientific.
The difficulty is ensuring that manufacturing is conducted "on a consistent basis and end up with the same product" by reducing the variability in the process, Newman told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.
Higher yields will lower the cost of therapies, Newman said, but there are major differences between smaller scale and large-scale production. FujiFilm Irvine Scientific is working with its customers as they look to scale up manufacturing and tackle supply chain, logistics, and raw material challenges.
Watch the video below to learn more.
Copyright © 2022 scienceboard.net